Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC raised its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 160.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,300,000 shares of the company's stock after purchasing an additional 800,000 shares during the quarter. Affinity Asset Advisors LLC owned 1.92% of Perspective Therapeutics worth $4,147,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CATX. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics in the 4th quarter worth approximately $33,000. Aigen Investment Management LP acquired a new position in Perspective Therapeutics in the 4th quarter valued at $34,000. National Bank of Canada FI increased its stake in Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after purchasing an additional 10,998 shares during the last quarter. Vontobel Holding Ltd. purchased a new position in Perspective Therapeutics during the fourth quarter worth about $51,000. Finally, Trueblood Wealth Management LLC boosted its stake in Perspective Therapeutics by 37.0% in the 4th quarter. Trueblood Wealth Management LLC now owns 22,236 shares of the company's stock worth $71,000 after buying an additional 6,000 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Wednesday, March 26th. Brookline Capital Management raised Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Finally, Cantor Fitzgerald upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $12.75.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock traded up $0.09 during midday trading on Friday, hitting $1.94. 806,996 shares of the company were exchanged, compared to its average volume of 1,020,947. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $19.05. The company's fifty day moving average price is $2.39 and its 200-day moving average price is $5.11.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Juan Graham bought 33,333 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The stock was bought at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the purchase, the chief financial officer now owns 35,354 shares in the company, valued at $79,546.50. This represents a 1,649.33 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert F. Williamson III purchased 22,192 shares of the company's stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.27 per share, with a total value of $50,375.84. Following the purchase, the director now owns 70,837 shares of the company's stock, valued at approximately $160,799.99. The trade was a 45.62 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 115,696 shares of company stock valued at $256,344. Corporate insiders own 3.52% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.